Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Apr 24 04:00PM ET
3.63
Dollar change
0.00
Percentage change
0.00
%
Index- P/E- EPS (ttm)-0.37 Insider Own1.29% Shs Outstand14.50M Perf Week13.08%
Market Cap52.64M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float14.31M Perf Month109.83%
Income-5.34M PEG- EPS next Q- Inst Own81.53% Short Float39.57% Perf Quarter128.59%
Sales0.00M P/S- EPS this Y- Inst Trans11.34% Short Ratio3.98 Perf Half Y83.33%
Book/sh2.55 P/B1.42 EPS next Y- ROA-13.19% Short Interest5.66M Perf Year85.20%
Cash/sh2.58 P/C1.41 EPS next 5Y- ROE-13.57% 52W Range1.56 - 3.88 Perf YTD113.53%
Dividend Est.- P/FCF- EPS past 5Y48.59% ROI-14.34% 52W High-6.44% Beta0.90
Dividend TTM- Quick Ratio59.01 Sales past 5Y0.00% Gross Margin- 52W Low132.69% ATR (14)0.20
Dividend Ex-Date- Current Ratio59.01 EPS Y/Y TTM46.28% Oper. Margin0.00% RSI (14)82.01 Volatility6.10% 6.84%
Employees5 Debt/Eq0.01 Sales Y/Y TTM- Profit Margin- Recom1.00 Target Price17.00
Option/ShortYes / Yes LT Debt/Eq0.01 EPS Q/Q7.85% Payout- Rel Volume0.00 Prev Close3.63
Sales Surprise- EPS Surprise- Sales Q/Q- EarningsOct 18 AMC Avg Volume1.42M Price3.63
SMA2022.68% SMA5065.81% SMA20084.74% Trades Volume0 Change0.00%
Date Action Analyst Rating Change Price Target Change
Feb-27-18Initiated Ascendiant Capital Markets Buy $2
Oct-09-13Initiated Dawson James Buy $3.75
Apr-03-24 02:30PM
12:00PM
07:30AM
Feb-01-24 04:35PM
Oct-18-23 04:25PM
04:25PM Loading…
Jul-21-23 04:25PM
Jul-13-23 11:30AM
Apr-24-23 04:25PM
Feb-24-23 04:20PM
Feb-03-23 10:19AM
Dec-19-22 04:05PM
Nov-14-22 09:24AM
Oct-28-22 04:15PM
Aug-02-22 04:15PM
Jul-18-22 06:14AM
04:05PM Loading…
Jun-21-22 04:05PM
May-05-22 04:15PM
May-02-22 04:15PM
Apr-18-22 04:30PM
Apr-05-22 01:35AM
Apr-01-22 07:09AM
Mar-31-22 04:15PM
Mar-14-22 04:15PM
Mar-07-22 04:30PM
Feb-08-22 04:21AM
Jan-04-22 08:30AM
Dec-02-21 08:30AM
Nov-20-21 07:01AM
Nov-09-21 04:15PM
Nov-02-21 04:15PM
07:03AM Loading…
Oct-29-21 07:03AM
06:26AM
Oct-28-21 04:30PM
Sep-16-21 08:30AM
Aug-16-21 08:05AM
Aug-12-21 01:15AM
Aug-09-21 08:00AM
Aug-04-21 04:15PM
Jul-28-21 08:00AM
Jul-13-21 08:00AM
Jul-09-21 08:00AM
Jul-08-21 11:20AM
Jul-07-21 08:00AM
Jun-23-21 09:35AM
May-11-21 04:15PM
May-05-21 04:05PM
May-03-21 04:30PM
Mar-18-21 04:30PM
Feb-13-21 01:09AM
Dec-15-20 08:30AM
Dec-09-20 05:40PM
Nov-23-20 12:28PM
08:30AM
Nov-02-20 08:30AM
Oct-07-20 08:30AM
Oct-05-20 04:30PM
Sep-21-20 08:00AM
Aug-17-20 08:49AM
Aug-12-20 08:00AM
Aug-05-20 04:15PM
Jul-07-20 08:30AM
Jun-03-20 09:56AM
09:56AM
Jun-01-20 08:20AM
May-29-20 12:24PM
09:59AM
May-28-20 04:19PM
12:14PM
10:27AM
08:00AM
May-07-20 08:30AM
May-06-20 04:30PM
Feb-18-20 04:30PM
Feb-01-20 08:31AM
Nov-06-19 04:10PM
Nov-03-19 08:47AM
Sep-12-19 08:30AM
Sep-11-19 08:30AM
Sep-04-19 01:37PM
Aug-21-19 09:49AM
Aug-01-19 04:30PM
Jun-04-19 07:09AM
May-13-19 09:00AM
May-08-19 04:30PM
May-01-19 08:30AM
Apr-23-19 08:30AM
Mar-18-19 08:30AM
Mar-06-19 08:00AM
Feb-27-19 04:15PM
Feb-20-19 07:30AM
Jan-16-19 08:30AM
Dec-26-18 11:47AM
Dec-20-18 04:01PM
Nov-14-18 04:30PM
Nov-12-18 08:30AM
Nov-05-18 08:30AM
Oct-10-18 04:16PM
Oct-02-18 08:00AM
Sep-18-18 08:30AM
Aug-09-18 04:15PM
ARCA biopharma, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of targeted therapies for cardiovascular diseases. The firm focuses on the cardiovascular pathophysiology, molecular genetics, and clinical development. Its product candidate, Gencaro is a pharmacologic beta-blocker and mild vasodilator, which is developed for the treatment of chronic heart failure and other indications. The company was founded by Michael R. Bristow and Christopher David Ozeroff in 1992 and is headquartered in Westminster, CO.